1
|
Tassano M, Camacho X, Freire T, Perroni C, da Costa V, Cabrera M, García MF, Fernandez M, Gambini JP, Cabral P, Osinaga E. Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors. Cancer Biother Radiopharm 2024. [PMID: 38215243 DOI: 10.1089/cbr.2023.0138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2024] Open
Abstract
Aim: ChiTn, a mouse/human chimeric anti-Tn monoclonal antibody, was radiolabeled with iodine-131 (131I) and technetium-99m (99mTc) to assess its biodistribution and internalization in Tn-expressing (Tn+) and wild-type (Tn-) LL/2 lung cancer cells. Results: Selective accumulation and gradual internalization of ChiTn were observed in Tn+ cells. Biodistribution in mice with both Tn+ or Tn- lung tumors indicated that the uptake of radiolabeled ChiTn within tumors increased over time. Dual-labeling experiments with 99mTc and 131I showed different biodistribution patterns, with 99mTc exhibiting higher values in the liver, spleen, and kidneys, while 131I showed higher uptake in the thyroid and stomach. However, tumor uptake did not significantly differ between Tn+ and Tn- tumors. To improve tumor targeting, Losartan, an antihypertensive drug known to enhance tumor perfusion and drug delivery, was investigated. Biodistribution studies in Losartan-treated mice revealed significantly higher radiolabeled ChiTn uptake in Tn+ tumors. No significant changes were observed in the uptake of the control molecule IgG-HYNIC-99mTc. Conclusions: These findings demonstrate the enhanced tumor targeting of radiolabeled ChiTn in Losartan-treated mice with Tn-expressing lung tumors. They highlight the potential of ChiTn as a theranostic agent for cancer treatment and emphasize the importance of Losartan as an adjunctive treatment to improve tumor perfusion and drug delivery.
Collapse
Affiliation(s)
- Marcos Tassano
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Ximena Camacho
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Teresa Freire
- Laboratorio de Inmunomodulacion y Desarrollo de Vacunas, Departamento de Inmunobiología, Facultad de Medicina, Universidad de La República, Montevideo, Uruguay
| | - Carolina Perroni
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Valeria da Costa
- Laboratorio de Inmunomodulacion y Desarrollo de Vacunas, Departamento de Inmunobiología, Facultad de Medicina, Universidad de La República, Montevideo, Uruguay
| | - Mirel Cabrera
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Maria Fernanda García
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Marcelo Fernandez
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Pablo Cabral
- Area de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Eduardo Osinaga
- Laboratorio de Inmunomodulacion y Desarrollo de Vacunas, Departamento de Inmunobiología, Facultad de Medicina, Universidad de La República, Montevideo, Uruguay
- Laboratorio de Glicobiología e Inmunología Tumoral, Institut Pasteur de Montevideo, Montevideo, Uruguay
| |
Collapse
|
2
|
Rodriguez G, Couto M, Fernandez M, Tassano M, Cabrera M, Cabral P, Melián MG, Cerecetto H. Exploring new strategies for technetium radiolabeled [1,2,4,5] tetrazines. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)02211-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
3
|
Chaboche PA, Pointurier F, Sabatier P, Foucher A, Tiecher T, Minella JPG, Tassano M, Hubert A, Morera S, Guédron S, Ardois C, Boulet B, Cossonnet C, Cabral P, Cabrera M, Chalar G, Evrard O. 240Pu/ 239Pu signatures allow refining the chronology of radionuclide fallout in South America. Sci Total Environ 2022; 843:156943. [PMID: 35753489 DOI: 10.1016/j.scitotenv.2022.156943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 06/18/2022] [Accepted: 06/20/2022] [Indexed: 06/15/2023]
Abstract
Atmospheric nuclear tests (1945-1980) have led to radioactive fallout across the globe. French tests in Polynesia (1966-1974) may influence the signature of fallout in South America in addition to those conducted by USA and former USSR until 1963 in the Northern hemisphere. Here, we compiled the 240Pu/239Pu atom ratios reported for soils of South America and conducted additional measurements to examine their latitudinal distributions across this continent. Significantly lower ratio values were found in the 20-45° latitudinal band (0.04 to 0.13) compared to the rest of the continent (up to 0.20) and attributed to the contribution of the French atmospheric tests to the ultra-trace plutonium levels found in these soils. Based on sediment cores collected in lakes of Chile and Uruguay, we show the added value of measuring 240Pu/239Pu atom ratios to refine the age models of environmental archives in this region of the world.
Collapse
Affiliation(s)
- Pierre-Alexis Chaboche
- Laboratoire des Sciences du Climat et de l'Environnement (LSCE/IPSL), Unité Mixte de Recherche 8212 (CEA-CNRS-UVSQ), Université Paris-Saclay, Gif-sur-Yvette, France.
| | | | - Pierre Sabatier
- EDYTEM, Université Savoie-Mont Blanc, CNRS, 73370 Le Bourget du Lac, France
| | - Anthony Foucher
- Laboratoire des Sciences du Climat et de l'Environnement (LSCE/IPSL), Unité Mixte de Recherche 8212 (CEA-CNRS-UVSQ), Université Paris-Saclay, Gif-sur-Yvette, France
| | - Tales Tiecher
- Department of Soil Science, Federal University of Rio Grande do Sul, Bento Gonçalves Ave. 7712, 91540-000 Porto Alegre, RS, Brazil
| | - Jean P G Minella
- Department of Soils, Federal University of Santa Maria, 97105-900 Santa Maria, Brazil
| | - Marcos Tassano
- Laboratorio de Radioquímica, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | | | - Sergio Morera
- Instituto Geofísico del Perú, Universidad Nacional Agraria La Molina, 15081 Lima, Peru
| | - Stéphane Guédron
- Univ. Grenoble Alpes, Univ. Savoie Mont Blanc, CNRS, IRD, IFSTTAR, ISTerre, 38000 Grenoble, France
| | - Christophe Ardois
- Institut de Radioprotection et de Sûreté nucléaire, Bât 501, bois des Rames, 91400 Orsay, France
| | - Béatrice Boulet
- Institut de Radioprotection et de Sûreté nucléaire, Bât 501, bois des Rames, 91400 Orsay, France
| | - Catherine Cossonnet
- Institut de Radioprotection et de Sûreté nucléaire, Bât 501, bois des Rames, 91400 Orsay, France
| | - Pablo Cabral
- Laboratorio de Radioquímica, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Mirel Cabrera
- Laboratorio de Radioquímica, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Guillermo Chalar
- Sección Limnología, Facultad de Ciencias, Universidad de la República, Uruguay
| | - Olivier Evrard
- Laboratoire des Sciences du Climat et de l'Environnement (LSCE/IPSL), Unité Mixte de Recherche 8212 (CEA-CNRS-UVSQ), Université Paris-Saclay, Gif-sur-Yvette, France
| |
Collapse
|
4
|
Lecot N, Rodríguez G, Stancov V, Fernández M, González M, Glisoni RJ, Cabral P, Cerecetto H. Development of fluorescent- and radio-traceable T1307-polymeric micelles as biomedical agents for cancer diagnosis: biodistribution on 4T1 tumor-bearing mice. BRAZ J PHARM SCI 2022. [DOI: 10.1590/s2175-97902022e191055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | - Hugo Cerecetto
- Universidad de la República, Uruguay; Universidad de la República, Uruguay
| |
Collapse
|
5
|
Lecot N, Dávila B, Sánchez C, Fernández M, González M, Cabral P, Cerecetto H, Glisoni R. Development and Evaluation of 2-Amino-7-Fluorophenazine 5,10-Dioxide Polymeric Micelles as Antitumoral Agents for 4T1 Breast Cancer. Polymers (Basel) 2021; 14:71. [PMID: 35012094 PMCID: PMC8747360 DOI: 10.3390/polym14010071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 12/18/2021] [Accepted: 12/22/2021] [Indexed: 11/23/2022] Open
Abstract
2-Amino-7-fluorophenazine 5,10-dioxide (FNZ) is a bioreducible prodrug, poorly soluble in water, with potential anticancer activity on hypoxic-tumors. This poor solubility limits its potential applications in clinic. Amphiphilic pristine polymeric micelles (PMs) based on triblock copolymers Pluronic® and Tetronic®, glycosylated derivatives and their mixtures with preformed-liposomes (LPS), were analyzed as strategies to improve the bioavailability of FNZ. FNZ encapsulations were performed and the obtaining nanostructures were characterized using UV-visible spectroscopy (UV-VIS), Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS). The most promising nanoformulations were analyzed for their potential toxicity and pharmacologically, at 20 mg/kg FNZ-doses, in a stage-IV murine metastatic-breast tumor model. The results revealed that the solubility of the encapsulated-FNZ increased up to 14 times and the analysis (UV-VIS, DLS and TEM) confirmed the interaction between vehicles and FNZ. In all the cases appropriate encapsulation efficiencies (greater than 75%), monodisperse nanometric particle sizes (PDI = 0.180-0.335), adequate Z-potentials (-1.59 to -26.4 mV), stabilities and spherical morphologies were obtained. The in vitro profile of FNZ controlled releases corresponded mainly to a kinetic Higuchi model. The in vitro/in vivo biological studies revealed non-toxicity and relevant tumor-weight diminution (up to 61%).
Collapse
Affiliation(s)
- Nicole Lecot
- Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (P.C.); (H.C.)
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (B.D.); (C.S.); (M.G.)
| | - Belén Dávila
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (B.D.); (C.S.); (M.G.)
| | - Carina Sánchez
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (B.D.); (C.S.); (M.G.)
| | - Marcelo Fernández
- Laboratorio de Experimentación Animal, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay;
| | - Mercedes González
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (B.D.); (C.S.); (M.G.)
| | - Pablo Cabral
- Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (P.C.); (H.C.)
| | - Hugo Cerecetto
- Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (P.C.); (H.C.)
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay; (B.D.); (C.S.); (M.G.)
| | - Romina Glisoni
- Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
- Instituto de Nanobiotecnología (NANOBIOTEC), CONICET-Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
| |
Collapse
|
6
|
Camacho X, Perroni C, Machado CL, de Godoi Carneiro C, de Souza Junqueira M, Faria D, García MF, Fernández M, Oddone N, Benech J, Buchpiguel CA, Cerecetto H, Chammas R, Riva E, Cabral P, Gambini JP. 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents. Anticancer Agents Med Chem 2021; 21:1883-1893. [PMID: 33397271 DOI: 10.2174/1871520621999210104181238] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 10/07/2020] [Accepted: 11/01/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Multiple Myeloma (MM) is a malignant hematologic disorder and the second most common blood cancer. Interleukin-6 (IL-6) has been identified as a crucial factor for the proliferation and survival of MM cells and the overexpression of IL-6 receptor is being studied as a molecular target for therapeutic and diagnostic use in myelomas and other comorbidities. Tocilizumab is a humanized monoclonal antibody that binds IL-6R. OBJECTIVE We aim to label and evaluate Fab(Tocilizumab) with 99mTechnetium or Cy7 as potential MM imaging agents. METHODS IL-6R distribution was analyzed by Laser Confocal Microscopy (LCM) in MM cell lines. Fab(Tocilizumab) was produced by the digestion of Tocilizumab with papain for 24h at 37°C, derivatized with NHS-HYNIC-Tfa and radiolabeled with 99mTc. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and SPECT/CT were performed. Also, Fab(Tocilizumab) was labeled with Cy7 for in vivo fluorescence imaging up to 72h. RESULTS LCM analysis demonstrates IL-6R distribution on MM cell lines. Incubation with papain resulted in complete digestion of Tocilizumab and exhibited a good purity and homogeneity. Radiolabeling with 99mTc via NHS-HYNIC-Tfa was found to be fast, easy, reproducible and stable, revealing high radiochemical purity and without interfering with IL-6R recognition. Biodistribution and SPECT/CT studies showed a quick blood clearance and significant kidney and MM engrafted tumor uptake. Cy7-Fab(Tocilizumab) fluorescent imaging allowed MM1S tumor identification up to 72h p.i. CONCLUSION These new molecular imaging agents could potentially be used in the clinical setting for staging and follow-up of MM through radioactive whole-body IL-6R expression visualization in vivo. The fluorescent version could be used for tissue sample evaluation and to guide surgical excision, if necessary.
Collapse
Affiliation(s)
- Ximena Camacho
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Carolina Perroni
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Camila L Machado
- Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP, Sao Paulo, Brazil
| | - Camila de Godoi Carneiro
- Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP, Sao Paulo, Brazil
| | - Mara de Souza Junqueira
- Laboratorio de Oncologia Experimental, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo Nº 455- Cerqueira Cesar - CEP: 01246903, Sao Paulo, Brazil
| | - Daniele Faria
- Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP, Sao Paulo, Brazil
| | - María F García
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Marcelo Fernández
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Natalia Oddone
- Laboratorio de Senalizacion Celular y Nanobiologia, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay
| | - Juan Benech
- Laboratorio de Senalizacion Celular y Nanobiologia, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay
| | - Carlos A Buchpiguel
- Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP, Sao Paulo, Brazil
| | - Hugo Cerecetto
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Roger Chammas
- Laboratorio de Oncologia Experimental, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo Nº 455- Cerqueira Cesar - CEP: 01246903, Sao Paulo, Brazil
| | - Eloisa Riva
- Clinica Hematologica. Hospital de Clinicas. Facultad de Medicina. Universidad de la Republica, Montevideo, Uruguay
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | - Juan P Gambini
- Centro de Medicina Nuclear e Imagenologia Molecular, Hospital de Clinicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay
| |
Collapse
|
7
|
Cabrera M, Lecot N, Fernández M, Gambini JP, Porcal W, Cabral P. 99mTc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer. AAPS PharmSciTech 2021; 22:115. [PMID: 33763814 DOI: 10.1208/s12249-021-01984-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 03/08/2021] [Indexed: 12/13/2022] Open
Abstract
Nanomedicine is a highly demanded discipline. Liposomes have seen an increased attention due to their physicochemical properties that allow them to act as nanocarriers of drugs and also of radioisotopes that can be used to diagnose and treat cancer. In order to obtain a novel permeability cancer imaging agent based on 99mTc-labeled liposomes, we describe microwave-assisted synthesis of stearyl 6-(benzylidenehydrazinyl) nicotinamide lipid, which was included in two formulations: nanometric hydrazinonicotinic acid (HYNIC) liposome and its PEGylated coated analogue, HYNIC-PEG liposome. Radiolabeling with 99mTc via stearyl 6-(benzylidenehydrazinyl) nicotinamide was found to be easy, reproducible, and stable, revealing high radiochemical purity (94 ± 1.7%) for both liposomal formulations. Biodistribution at 4 h and 24 h and scintigraphic images at 4 h were performed in normal and melanoma-bearing C57BL/6 mice. Biodistribution studies at 4 h showed tumor uptake of 99mTc-HYNIC liposome and 99mTc-HYNIC-PEG liposome (1.1 ± 0.6 and 2.5 ± 0.4, respectively) and also at 24 h p.i. (1.8 ± 0.5 and 3.0 ± 1.1, respectively). Scintigraphic images showed appreciable tumor uptake in melanoma tumor-bearing mice with both liposomal formulations. Our results show that 99mTc stearyl 6-(benzylidenehydrazinyl) nicotinamide liposomes can be used as diagnostic noninvasive in vivo tumor-targeting agents capable of evaluating tumor permeability and development who can be used in personalized chemotherapy planning.
Collapse
|
8
|
Fernanda García M, Souza Junqueira M, Silva Mororó J, Camacho X, Paula Faria D, Godoi Carneiro C, Gallazzi F, Chammas R, Quinn T, Cabral P, Cerecetto H. Radio‐ and Fluorescent‐Labeling of Rituximab Based on the Inverse Electron Demand Diels‐Alder Reaction. ChemistrySelect 2021. [DOI: 10.1002/slct.202100042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- María Fernanda García
- Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República Mataojo 2055 11400 Montevideo Uruguay
| | - Mara Souza Junqueira
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo Faculdade de Medicina Universidade de São Paulo São Paulo Brazil
| | - Janio Silva Mororó
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo Faculdade de Medicina Universidade de São Paulo São Paulo Brazil
| | - Ximena Camacho
- Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República Mataojo 2055 11400 Montevideo Uruguay
| | - Daniele Paula Faria
- Laboratório de Medicina Nuclear (LIM43), Faculdade de Medicina Universidade de São Paulo São Paulo Brazil
| | - Camila Godoi Carneiro
- Laboratório de Medicina Nuclear (LIM43), Faculdade de Medicina Universidade de São Paulo São Paulo Brazil
| | - Fabio Gallazzi
- Molecular Interactions Core and Department of Biochemistry University of Missouri Columbia MO 65211 USA
| | - Roger Chammas
- Laboratório de Medicina Nuclear (LIM43), Faculdade de Medicina Universidade de São Paulo São Paulo Brazil
| | - Thomas Quinn
- Molecular Interactions Core and Department of Biochemistry University of Missouri Columbia MO 65211 USA
| | - Pablo Cabral
- Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República Mataojo 2055 11400 Montevideo Uruguay
| | - Hugo Cerecetto
- Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República Mataojo 2055 11400 Montevideo Uruguay
| |
Collapse
|
9
|
Sicco E, Baez J, Ibarra M, Fernández M, Cabral P, Moreno M, Cerecetto H, Calzada V. Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies. Cancer Biother Radiopharm 2021; 35:262-270. [PMID: 32407201 DOI: 10.1089/cbr.2019.3402] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: Aptamers represent an emerging class of oligonucleotides that have the ability to bind ligands with high affinity. Sgc8-c aptamer recognizes PTK7, a member of the catalytically defective receptor protein tyrosine kinase family that is upregulated in various cancers, including hemato-oncological malignancies. Herein, an Sgc8-c-NOTA-radiolabeled probe was prepared for theranostic purpose. Materials and Methods: In this work, an Sgc8-c-radiolabeled probe against PTK7 was prepared, and biological evaluations-pharmacokinetic studies, biodistribution analysis, and in vivo molecular imaging-were performed. To obtain the radiolabeled probe, a modified 5'-amino-derivative of the Sgc8-c aptamer was bound to the metal chelator NOTA, and subsequently labeled with 67Ga with high yield and radiochemical purity. The precursor, Sgc8-c-NOTA, the radio probe Sgc8-c-NOTA-67Ga, and its nonradioactive complex, Sgc8-c-NOTA-69/71Ga, were purified by reverse-phase high-performance liquid chromatography and characterized by electrospray ionization mass spectrometry. The binding ability of Sgc8-c-NOTA-67Ga was studied in vitro against purified PTK7 receptor. In addition, the binding was also evidenced against the hemato-oncological A20 cell line, derived from B lymphocytes, and the corresponding A20-green fluorescent protein (GFP)-transfected cells. The proof of concept was performed on A20-GFP tumor-bearing mice, in which the biodistribution of the radiolabeled probe was evaluated through imaging, using X-ray, fluorescence, and γ modalities. The specific uptake of the probe was confirmed by blocking with the Sgc8-c aptamer in an in vivo competition assay. Results: The biodistribution results showed considerable uptake in tumor since 2 h, with highest at 48 h postinjection. However, the blood and muscle ID/g (injected dose per gram of tissue) activities were decreasing with time and tumor/no-target ratios increasing to 20 at 24 h postinjection. These results are consistent with the in vivo images. Conclusions: This study supports the utility of Sgc8-c-NOTA radiolabeled as a theranostic agent.
Collapse
Affiliation(s)
- Estefanía Sicco
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Jessica Baez
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Manuel Ibarra
- Departamento de Ciencias Farmaceuticas, Facultad de Química, Universidad de la República, Montevideo, Uruguay
| | - Marcelo Fernández
- Laboratorio de Experimentacion Animal, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - María Moreno
- Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Hugo Cerecetto
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | - Victoria Calzada
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| |
Collapse
|
10
|
Kovacs L, Cabral P, Chammas R. Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations. PLoS One 2020; 15:e0240455. [PMID: 33048944 PMCID: PMC7553290 DOI: 10.1371/journal.pone.0240455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 09/25/2020] [Indexed: 11/29/2022] Open
Abstract
The presence of a high number of macrophages within solid tumors is often significantly associated with poor prognosis and predict treatment failure for chemotherapy and radiotherapy. Macrophages are innate immune cells capable of performing diverse functions depending on the different signals from the microenvironment. The classically activated macrophage is commonly present during the early stages of tumor development while alternatively activated macrophages are associated with more advanced tumors. The distinction of the antitumoral macrophages from the pro-tumoral macrophages is not absolute. However, they have different cell surface markers such as mannose receptor (MRC1 or CD206) abundantly expressed by macrophages treated with interleukin-4 (IL-4). The important roles of macrophages in cancers suggest that it is important to develop novel therapies that target these cells. In the present study, we designed a probe using Polyamidoamine (PAMAM) fifth-generation (G5) dendrimers conjugated with mannose, Cyanine 7 (Cy7), and hydrazinonicotinamide (HYNIC) for target macrophages with high expression of MRC1 in the tumor. The intracellular uptake of 99mTc-HYNIC-dendrimer-mannose-Cy7 through the interaction with MRC1 in bone marrow-derived macrophages (BMDMs) untreated or treated with lipopolysaccharides (LPS) + interferon (IFN)γ or IL-4 was analyzed. Our results show that high-density mannose dendrimers are preferentially bound by macrophages treated by IFNγ and LPS that express lower levels of MRC1 than for macrophages treated by IL-4 that express high levels of MRC1. Furthermore, the intracellular 99mTc-HYNIC-dendrimer-mannose-Cy7 uptake in BMDMs was not inhibited in the presence of free mannose or glucose. This result suggests that 99mTc-HYNIC-dendrimer-mannose-Cy7 is not internalized via macrophage MRC1. Based on these findings, we concluded that MRC1 expression does not determine the uptake of high-density mannose dendrimers.
Collapse
Affiliation(s)
- Luciana Kovacs
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República, Montevideo, Uruguay
| | - Roger Chammas
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil
- Departamento de Radiologia e Oncologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
| |
Collapse
|
11
|
Couto M, Alamón C, Nievas S, Perona M, Dagrosa MA, Teixidor F, Cabral P, Viñas C, Cerecetto H. Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer. Chemistry 2020; 26:14335-14340. [PMID: 32738078 DOI: 10.1002/chem.202002963] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/26/2020] [Indexed: 12/17/2022]
Abstract
About 95 % of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells and found to be 4 times more cytotoxic than sunitinib and 1.7 times more effective than 10 B-boronophenylalanine fructose complex when the cells were irradiated with neutrons.
Collapse
Affiliation(s)
- Marcos Couto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Catalina Alamón
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Susana Nievas
- Department of Boron Neutron Capture Therapy, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina
| | - Marina Perona
- Department of Radiobiology, CNEA, Buenos Aires, Argentina
| | | | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), Campus UAB, 08193, Bellaterra, Spain
| | - Hugo Cerecetto
- Grupo de Química Orgánica Medicinal, Instituto de Química Biológica (IQB), Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Área de Radiofarmacia, Centro de Investigaciones Nucleares (CIN), Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| |
Collapse
|
12
|
Lin K, Cabral P, Ekpenyong O, Bader SE, Galvao J, Kim Y, Lu SX, Tam YT, Bruder M, Rearden P, Shankaran H, Beaumont M. A Surrogate Matrix-Based Approach Toward Multiplexed Quantitation of an sGC Stimulator and cGMP in Ocular Tissue and Plasma. Toxicol Pathol 2020; 49:544-554. [PMID: 32851936 DOI: 10.1177/0192623320948836] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A liquid chromatography-tandem mass spectrometry assay was developed and qualified for the multiplexed quantitation of a small molecule stimulator of soluble guanylate cyclase (sGC) and its target engagement biomarker, 3',5'-cyclic guanosine monophosphate (cGMP), in ocular tissues and plasma from a single surrogate matrix calibration curve. A surrogate matrix approach was used in this assay due to the limited quantities of blank ocular matrices in a discovery research setting. After optimization, the assay showed high accuracy, precision, and recovery as well as parallelism between the surrogate matrix and the biological matrices (rabbit plasma, vitreous, and retina-choroid). This assay provided pharmacokinetic and target engagement data after intravitreal administration of the sGC stimulator. The nitric oxide-sGC-cGMP pathway is a potential target to address glaucoma. Increasing sGC-mediated production of cGMP could improve aqueous humor outflow and ocular blood flow. The sGC stimulator showed dose-dependent exposure in rabbit vitreous, retina-choroid, and plasma. The cGMP exhibited a delayed yet sustained increase in vitreous humor but not retina-choroid. Multiplexed measurement of both pharmacokinetic and target engagement analytes reduced animal usage and provided improved context for interpreting PK and PD relationships.
Collapse
Affiliation(s)
- Kenneth Lin
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | - Pablo Cabral
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | | | | | - Joana Galvao
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | | | - Sherry X Lu
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | - Yu Tong Tam
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | - Marc Bruder
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | - Paul Rearden
- 2793Merck & Co., Inc, South San Francisco, CA, USA
| | | | | |
Collapse
|
13
|
Baldwin AE, Hayes N, Ostrander E, Magri R, Sass N, Dos Anjos Mesquita M, Martínez M, Juliani MC, Cabral P, Fleming M. Phosphatidylethanol Levels in Postpartum Women and Their Newborns in Uruguay and Brazil. Alcohol Clin Exp Res 2020; 44:1292-1299. [PMID: 32441809 DOI: 10.1111/acer.14339] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Revised: 03/16/2020] [Accepted: 03/27/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND There is increasing interest in the development of newborn screening tests to identify children at risk of fetal alcohol spectrum disorder (FASD) in order to provide these children with early intervention. Phosphatidylethanol (PEth) has emerged as a potential universal newborn screening candidate. METHODS The aim of this report was to present the results of a study designed to compare PEth levels in 1,140 postpartum women and their newborn infants in Montevideo, Uruguay, and Sao Paulo, Brazil. Self-report alcohol use during pregnancy data was collected, along with both maternal and newborn dried blood spot samples for PEth analysis. RESULTS The average age and parity of the women in the sample were 26 years of age and 2.3 pregnancies. For the Uruguay sample (n = 611), 45.8% of postpartum women had PEth levels ≥ 8 ng/ml with a mean positive PEth of 43.6 ng/ml. In contrast, 86.8% of the newborns had PEth levels ≥ 8 ng/ml, with a mean positive PEth of 77.4 ng/ml. For the Brazil sample (n = 529), 33.2% of women had PEth levels ≥ 8 ng/ml with a mean positive PEth of 31 ng/ml. In contrast, 76.9% of the Brazil newborns had PEth levels ≥ 8 ng/ml and 43.9% with a mean positive PEth of 61.1 ng/ml. PEth levels were significantly higher in newborns compared with their postpartum mothers in both the Uruguay and Brazil samples. Self-reported third-trimester alcohol was 6% in the Uruguay sample and 9.1% in the Brazil sample compared with positive maternal PEth levels in 45.8% and 33.2%, respectively. CONCLUSIONS Clinicians may want to consider newborn PEth screening in high-risk populations where prenatal alcohol use is common. The mechanism underlying significantly higher PEth levels in newborns compared with their mothers is not known.
Collapse
Affiliation(s)
- Aileen E Baldwin
- United States Drug Testing Laboratories, Inc., (AEB), Des Plaines, Illinois
| | - Nicole Hayes
- UCLA Counseling and Psychological Services, (NH), University of California Los Angeles, Los Angeles, California
| | - Erika Ostrander
- Department of Psychiatry and Behavioral Sciences, (EO, MF), Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Raquel Magri
- Facultad de Medicina, (RM), Universidad de la República, Montevideo, Uruguay
| | - Nelson Sass
- Universidade Federal de São Paulo, (NS), Clínica Obstétrica da Maternidade Escola de Vila Nova Cachoeirinha, São Paulo, Brazil
| | | | - Monica Martínez
- Facultad de Odontologia, (MM), Universidad de la República, Montevideo, Uruguay
| | | | - Pablo Cabral
- Hospital General de las Fuerzas Armadas de Uruguay, (MCJ, PC), Montevideo, Uruguay
| | - Michael Fleming
- Department of Psychiatry and Behavioral Sciences, (EO, MF), Northwestern University Feinberg School of Medicine, Chicago, Illinois
| |
Collapse
|
14
|
Lecot N, Glisoni R, Oddone N, Benech J, Fernández M, Gambini JP, Cabral P, Sosnik A. Glucosylated Polymeric Micelles Actively Target a Breast Cancer Model. Adv Therap 2020. [DOI: 10.1002/adtp.202000010] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Nicole Lecot
- Laboratorio de ATN en Bioquímica y Biotecnología, Centro de Investigaciones Nucleares Facultad de Ciencias Universidad de la República Mataojo 2055 Montevideo 11400 Uruguay
| | - Romina Glisoni
- Universidad de Buenos Aires Facultad de Farmacia y Bioquímica, Cátedra de Tecnología Farmacéutica II, NANOBIOTEC‐CONICET Junín 956 Ciudad Autónoma de Buenos Aires C1113AAD Argentina
| | - Natalia Oddone
- Laboratorio de Señalización Celular y Nanobiología Instituto de Investigaciones Biológicas Clemente Estable. Av. Italia 3318 Montevideo 11600 Uruguay
| | - Juan Benech
- Laboratorio de Señalización Celular y Nanobiología Instituto de Investigaciones Biológicas Clemente Estable. Av. Italia 3318 Montevideo 11600 Uruguay
| | - Marcelo Fernández
- Laboratorio de Experimentación Animal, Centro de Investigaciones Nucleares, Facultad de Ciencias Universidad de la República Mataojo 2055 Montevideo 11400 Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear, Hospital de Clínicas, Facultad de Medicina Universidad de la Republica Av. Italia s/n Montevideo 11600 Uruguay
| | - Pablo Cabral
- Laboratorio de ATN en Bioquímica y Biotecnología, Centro de Investigaciones Nucleares Facultad de Ciencias Universidad de la República Mataojo 2055 Montevideo 11400 Uruguay
- Centro de Medicina Nuclear, Hospital de Clínicas, Facultad de Medicina Universidad de la Republica Av. Italia s/n Montevideo 11600 Uruguay
| | - Alejandro Sosnik
- Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering Technion‐Israel Institute of Technology Technion City Haifa 320003 Israel
| |
Collapse
|
15
|
Dávila B, Sánchez C, Fernández M, Cerecetto H, Lecot N, Cabral P, Glisoni R, González M. Selective Hypoxia‐Cytotoxin 7‐Fluoro‐2‐Aminophenazine 5,10‐Dioxide: Toward “Candidate‐to‐Drug” Stage in the Drug‐Development Pipeline. ChemistrySelect 2019. [DOI: 10.1002/slct.201902601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Belén Dávila
- Laboratorio de Química Orgánica MedicinalInstituto de Química Biológica. Facultad de CienciasUniversidad de la República. Iguá 4225 Montevideo 11400 Uruguay
| | - Carina Sánchez
- Laboratorio de Química Orgánica MedicinalInstituto de Química Biológica. Facultad de CienciasUniversidad de la República. Iguá 4225 Montevideo 11400 Uruguay
| | - Marcelo Fernández
- Laboratorio de Experimentación AnimalCentro de Investigaciones Nucleares. Facultad de CienciasUniversidad de la República. Mataojo 2055 Montevideo 11400 Uruguay
| | - Hugo Cerecetto
- Laboratorio de Química Orgánica MedicinalInstituto de Química Biológica. Facultad de CienciasUniversidad de la República. Iguá 4225 Montevideo 11400 Uruguay
- Área de RadiofarmaciaCentro de Investigaciones Nucleares. Facultad de CienciasUniversidad de la República. Mataojo 2055 Montevideo 11400 Uruguay
| | - Nicole Lecot
- Laboratorio de Química Orgánica MedicinalInstituto de Química Biológica. Facultad de CienciasUniversidad de la República. Iguá 4225 Montevideo 11400 Uruguay
- Laboratorio de Técnicas Nucleareas Aplicadas a Bioquímica y BiotecnologíaCentro de Investigaciones Nucleares. Facultad de CienciasUniversidad de la República. Mataojo 2055 Montevideo 11400 Uruguay
| | - Pablo Cabral
- Área de RadiofarmaciaCentro de Investigaciones Nucleares. Facultad de CienciasUniversidad de la República. Mataojo 2055 Montevideo 11400 Uruguay
| | - Romina Glisoni
- Departamento de Tecnología FarmacéuticaCátedra de Tecnología Farmacéutica II. CONICETInstituto de Nanobiotecnología (NANOBIOTEC). Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires
| | - Mercedes González
- Laboratorio de Química Orgánica MedicinalInstituto de Química Biológica. Facultad de CienciasUniversidad de la República. Iguá 4225 Montevideo 11400 Uruguay
| |
Collapse
|
16
|
Tassano M, Oddone N, Fernández M, Porcal W, García MF, Martínez-López W, Benech JC, Cabral P. Evaluation of chromosomal aberrations induced by 188Re-dendrimer nanosystem on B16f1 melanoma cells. Int J Radiat Biol 2018; 94:664-670. [PMID: 29775404 DOI: 10.1080/09553002.2018.1478161] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
PURPOSE To study the rhenium-188 labeling of polyamidoamine (PAMAM) generation 4 (G4) dendrimer and its evaluation on biodistribution and chromosomal aberrations in melanoma cells induced by ionizing radiation as potential treatment agent. MATERIALS AND METHODS Dendrimers were first conjugated with Suc-HYNIC (succinimidyl 6-hydrazinopyridine-3-carboxylic acid hydrochloride). Dendrimer-HYNIC was then incubated with 188ReO4-. Biodistribution was performed administrating 188Re-dendrimer to normal (NM) or melanoma-bearing mice (MBM). Chromosome aberration test was conducted in order to measure treatment capacity of 188Re-dendrimer in melanoma cells. RESULTS Radiolabeling yield of dendrimer was approx. 70%. Biodistribution studies in NM showed blood clearance with hepatic and renal depuration. MBM showed a similar pattern of biodistribution with tumor uptake of 6% of injected dose. Aberrant metaphases quantified in control cells were 7%, increasing to 29.5% in cells treated with 15μCi (0.555 MBq) of 188Re-dendrimer for 24 h. CONCLUSIONS 188Re-dendrimer can produce double-stranded breaks in DNA induced by ionizing radiation in melanoma cells in vitro.
Collapse
Affiliation(s)
- Marcos Tassano
- a Area de Radiofarmacia, Facultad de Ciencias , Centro de Investigaciones Nucleares, Universidad de la República , Montevideo , Uruguay
| | - Natalia Oddone
- b Laboratorio de Señalización Celular y Nanobiología , Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura , Montevideo , Uruguay
| | - Marcelo Fernández
- a Area de Radiofarmacia, Facultad de Ciencias , Centro de Investigaciones Nucleares, Universidad de la República , Montevideo , Uruguay
| | - Williams Porcal
- d Departamento de Química Orgánica, Facultad de Química , Universidad de la República , Montevideo , Uruguay
| | - María Fernanda García
- a Area de Radiofarmacia, Facultad de Ciencias , Centro de Investigaciones Nucleares, Universidad de la República , Montevideo , Uruguay
| | - Wilner Martínez-López
- c Laboratorio de Epigenética e Inestabilidad Genómica , Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura , Montevideo , Uruguay
| | - Juan Claudio Benech
- b Laboratorio de Señalización Celular y Nanobiología , Instituto de Investigaciones Biológicas Clemente Estable, Ministerio de Educación y Cultura , Montevideo , Uruguay
| | - Pablo Cabral
- a Area de Radiofarmacia, Facultad de Ciencias , Centro de Investigaciones Nucleares, Universidad de la República , Montevideo , Uruguay
| |
Collapse
|
17
|
Teixeira V, Cabral P, Porcal W. Microwave-assisted solid-phase synthesis of nicotinyl hydrazones for use in radiochemistry of technetium-99m. ARKIVOC 2018. [DOI: 10.24820/ark.5550190.p010.065] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
18
|
Couto M, García MF, Alamón C, Cabrera M, Cabral P, Merlino A, Teixidor F, Cerecetto H, Viñas C. Cover Feature: Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment (Chem. Eur. J. 13/2018). Chemistry 2018. [DOI: 10.1002/chem.201706010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Marcos Couto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB; 08193 Bellaterra Spain
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - María Fernanda García
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Catalina Alamón
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
| | - Mauricio Cabrera
- Laboratorio de I + D de Moléculas Bioactivas, Centro Universitario Paysandú, CenUR Litoral Norte; Universidad de la República; 60000 Paysandú Uruguay
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Alicia Merlino
- Laboratorio de Química Teórica y Computacional, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
| | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB; 08193 Bellaterra Spain
| | - Hugo Cerecetto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB; 08193 Bellaterra Spain
| |
Collapse
|
19
|
García MF, Gallazzi F, Junqueira MDS, Fernández M, Camacho X, Mororó JDS, Faria D, Carneiro CDG, Couto M, Carrión F, Pritsch O, Chammas R, Quinn T, Cabral P, Cerecetto H. Synthesis of hydrophilic HYNIC-[1,2,4,5]tetrazine conjugates and their use in antibody pretargeting with99mTc. Org Biomol Chem 2018; 16:5275-5285. [DOI: 10.1039/c8ob01255e] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Pretargeted imaging is shown to be an attractive strategy to overcome disadvantages associated with traditional radioimmunoconjugates.
Collapse
|
20
|
Couto M, García MF, Alamón C, Cabrera M, Cabral P, Merlino A, Teixidor F, Cerecetto H, Viñas C. Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment. Chemistry 2017; 24:3122-3126. [PMID: 29194843 DOI: 10.1002/chem.201705181] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Indexed: 11/06/2022]
Abstract
New 1,7-closo-carboranylanilinoquinazoline hybrids have been identified as EGFR inhibitors, one of them with higher affinity than the parent compound erlotinib. The comparative docking analysis with compounds bearing bioisoster-substructures, demonstrated the relevance of the 3D aromatic-boron-rich moiety for interacting into the EGFR ATP binding region. The capability to accumulate in glioma cells, the ability to cross the blood-brain barrier and the stability on simulated biological conditions, render these molecules as lead compounds for further structural modifications to obtain dual action drugs to treat glioblastoma.
Collapse
Affiliation(s)
- Marcos Couto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB, 08193, Bellaterra, Spain.,Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - María Fernanda García
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Catalina Alamón
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Mauricio Cabrera
- Laboratorio de I + D de Moléculas Bioactivas, Centro Universitario Paysandú, CenUR Litoral Norte, Universidad de la República, 60000, Paysandú, Uruguay
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Alicia Merlino
- Laboratorio de Química TeóricayComputacional, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay
| | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB, 08193, Bellaterra, Spain
| | - Hugo Cerecetto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Área de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona-CSIC, Campus UAB, 08193, Bellaterra, Spain
| |
Collapse
|
21
|
Sicco E, Báez J, Margenat J, García F, Ibarra M, Cabral P, Moreno M, Cerecetto H, Calzada V. Derivatizations of Sgc8-c aptamer to prepare metallic radiopharmaceuticals as imaging diagnostic agents: Syntheses, isolations, and physicochemical characterizations. Chem Biol Drug Des 2017; 91:747-755. [PMID: 29080264 DOI: 10.1111/cbdd.13135] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 07/09/2017] [Accepted: 10/04/2017] [Indexed: 12/31/2022]
Abstract
Aptamers, oligonucleotides with the capability to bind to a target through non-covalent bonds with high affinity and specificity, have a great number of advantages as scaffold to prepare molecular imaging agents. In this sense, we have performed post-SELEX modifications of a truncated aptamer, Sgc8-c, which bind to protein tyrosine kinase 7 to obtain a specific molecular targeting probe for in vivo diagnosis and in vivo therapy. Herein, we describe the synthetic efforts to prepare conjugates between Sgc8-c and different metallic ions chelator moieties in short times, high purities, and adequate yields. The selected chelator moieties, derived from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, 2-benzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid, and 6-hydrazinonicotinic acid, were covalently attached at the 5'-aptamer position yielding the expected products which were stable in aqueous solution up to 75°C and in typical aptamer storage conditions at least for 30 days.
Collapse
Affiliation(s)
- Estefanía Sicco
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay.,Departamento de Desarrollo Biotecnológico, Facultad de Medicina, Instituto de Higiene, Universidad de la República, Montevideo, Uruguay
| | - Jessica Báez
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay.,Facultad de Química, Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos, Universidad de la República, Montevideo, Uruguay
| | - Jimena Margenat
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Fernanda García
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Manuel Ibarra
- Facultad de Química, Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos, Universidad de la República, Montevideo, Uruguay
| | - Pablo Cabral
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - María Moreno
- Departamento de Desarrollo Biotecnológico, Facultad de Medicina, Instituto de Higiene, Universidad de la República, Montevideo, Uruguay
| | - Hugo Cerecetto
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Victoria Calzada
- Área de Radiofarmacia, Facultad de Ciencias, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| |
Collapse
|
22
|
Hato T, Zollman A, Plotkin Z, El-Achkar TM, Maier BF, Pay SL, Dube S, Cabral P, Yoshimoto M, McClintick J, Dagher PC. Endotoxin Preconditioning Reprograms S1 Tubules and Macrophages to Protect the Kidney. J Am Soc Nephrol 2017; 29:104-117. [PMID: 29018138 DOI: 10.1681/asn.2017060624] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Accepted: 08/14/2017] [Indexed: 12/21/2022] Open
Abstract
Preconditioning with a low dose of endotoxin confers unparalleled protection against otherwise lethal models of sepsis. The mechanisms of preconditioning have been investigated extensively in isolated immune cells such as macrophages. However, the role of tissue in mediating the protective response generated by preconditioning remains unknown. Here, using the kidney as a model organ, we investigated cell type-specific responses to preconditioning. Compared with preadministration of vehicle, endotoxin preconditioning in the cecal ligation and puncture mouse model of sepsis led to significantly enhanced survival and reduced bacterial load in several organs. Furthermore, endotoxin preconditioning reduced serum levels of proinflammatory cytokines, upregulated molecular pathways involved in phagocytosis, and prevented the renal function decline and injury induced in mice by a toxic dose of endotoxin. The protective phenotype involved the clustering of macrophages around S1 segments of proximal tubules, and full renal protection required both macrophages and renal tubular cells. Using unbiased S1 transcriptomic and tissue metabolomic approaches, we identified multiple protective molecules that were operative in preconditioned animals, including molecules involved in antibacterial defense, redox balance, and tissue healing. We conclude that preconditioning reprograms macrophages and tubules to generate a protective environment, in which tissue health is preserved and immunity is controlled yet effective. Endotoxin preconditioning can thus be used as a discovery platform, and understanding the role and participation of both tissue and macrophages will help refine targeted therapies for sepsis.
Collapse
Affiliation(s)
| | | | | | - Tarek M El-Achkar
- Departments of Medicine and.,Cellular and Integrative Physiology, Indiana University, Indianapolis, Indiana.,Roudebush Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana
| | | | | | - Shataakshi Dube
- Department of Neurobiology, Duke University Medical School, Durham, North Carolina
| | - Pablo Cabral
- Miromatrix Medical Inc., Eden Prairie, Minnesota; and
| | - Momoko Yoshimoto
- Institute of Molecular Medicine, Center for Stem Cell Research and Regenerative Medicine, University of Texas Health Science Center at Houston, Houston, Texas
| | | | - Pierre C Dagher
- Departments of Medicine and .,Cellular and Integrative Physiology, Indiana University, Indianapolis, Indiana.,Roudebush Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana
| |
Collapse
|
23
|
Camacho X, Machado CL, García MF, Fernández M, Oddone N, Benech J, Gambini JP, Cerecetto H, Chammas R, Cabral P, Riva E. Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma. Anticancer Agents Med Chem 2017; 17:1267-1277. [PMID: 28270081 DOI: 10.2174/1871520617666170213144917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 10/17/2016] [Accepted: 02/02/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Multiple myeloma is the second most common hematological malignancy. Interleukin-6 (IL-6) is one of the key molecules related to growth, survival and proliferation of myeloma cells. Tocilizumab is a humanized monoclonal antibody directed against receptor of IL-6. OBJECTIVE To radiolabel Tocilizumab with 99mTechnetium as a potential imaging agents for MM. METHODS IL-6R expression was studied by laser confocal microscopy in MM cell lines (U266, NCI-H929 and MM1S). Tocilizumab was derivatized with NHS-HYNIC-Tfa and radiolabeling with 99mTc. Radiochemical stability was determined. In-vitro binding and immunoreactive fraction assays were performed. Biodistribution and SPECT/CT imaging were evaluated in healthy BALB/c and MM-bearing BALB/c nude mice. RESULTS LCM studies allowed us to demonstrate that U266, NCI-H929 and MM1S cells present high expression of IL-6R in cell membrane. Radiolabeling was carried out in a fast, reproducible, easy and stable way having high radiochemical purity and did not interfere with epitope recognition. The immunoreactive fraction of 99mTc- HYNIC-Tocilizumab was 86.35%. Biodistribution showed a high uptake in liver, spleen, gastrointestinal tract and kidneys. SPECT/CT imaging of MM-bearing BALB/c nude mice showed liver uptake and a high tumor selective uptake at 24 hours. CONCLUSIONS Our results support the potential role of 99mTc-HYNIC-Tocilizumb as a novel MM radiotracer for targeting IL-6 expression in-vivo. We describe the development of a formulation kit to radiolabeling monoclonal antibodies in a clinical setting. We hope that these novel molecular imaging agents will open the path to new diagnostic and therapeutic strategies for MM disease.
Collapse
Affiliation(s)
- Ximena Camacho
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo. Uruguay
| | - Camila Longo Machado
- Nuclear Medicine Medical Investigation Laboratory LIM43-Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP. Brazil
| | - Maria Fernanda García
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo. Uruguay
| | - Marcelo Fernández
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo. Uruguay
| | - Natalia Oddone
- Laboratorio de Señalización Celular y Nanobiología, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo. Uruguay
| | - Juan Benech
- Laboratorio de Señalización Celular y Nanobiología, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo. Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo. Uruguay
| | - Hugo Cerecetto
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo. Uruguay
| | - Roger Chammas
- Laboratório de Oncologia Experimental, Faculdade de Medicina, Universidade de São Paulo, Av. Dr. Arnaldo Nº 455- Cerqueira César - CEP: 01246903, São Paulo. Brazil
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo. Uruguay
| | - Eloisa Riva
- Clínica Hematológica. Hospital de Clínicas. Facultad de Medicina. Universidad de la República, Montevideo, Uruguay, Avenida Italia s/n, P.O. 11800, Montevideo. Uruguay
| |
Collapse
|
24
|
Teixeira V, Fernández M, Oddone N, Zhang X, Gallazzi F, Cerecetto H, Gambini JP, Porcal W, Cabral P, Quinn TP. The Effect of A Hexanoic Acid Linker Insertion on the Pharmacokinetics and Tumor Targeting Properties of the Melanoma Imaging Agent 99mTc-HYNIC-cycMSH. Anticancer Agents Med Chem 2017; 17:1144-1152. [PMID: 27924732 DOI: 10.2174/1871520616666161206144414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Revised: 11/03/2016] [Accepted: 11/25/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND Lactam cyclized alpha-melanocyte stimulating hormone (α-MSH) analogues exhibit high stability and affinity for the MC1-R receptors over expressed in melanoma cells. Recently, we reported a novel 99mTc-HYNIC-cycMSH4-13 analogue with the HYNIC chelator directly attached to the lactam cyclized ring. OBJECTIVE In this study we proposed the introduction of a 6-aminohexanoic acid (Ahx) linker between the HYNIC chelator and lactam cyclized peptide cycMSH4-13 to reduce steric hindrance and improve the melanoma targeting and imaging proprieties of the radiolabeled peptide. METHOD HYNIC-Ahx-cycMSH4-13 peptide was synthesized on an automated peptide synthesizer and displayed an IC50 of 0.3 nM using B16/F1 cells. The 99mTc/tricine radiolabeled peptide was examined for radiochemical purity, stability and cell binding. In vivo, biodistribution and planar gamma imaging studies were performed in B16/F1 melanoma tumor bearing C57BK mice. RESULTS 99mTc-HYNIC-Ahx-cycMSH4-13 was obtained with a radiochemical purity > 95%, was stable up to 24 h at room temperature and exhibited high binding and rapid internalization in B16/F1 cells. In vivo biodistribution studies showed a tumor uptake of 4.92 ± 0.92 % ID/g and 2.78 ± 1.48 % ID/g at 2 h and 4 h post injection, respectively. Whole-body clearance was rapid through urinary excretion. The melanoma tumors were clearly visualized by planar gamma imaging. CONCLUSION 99mTc-HYNIC-Ahx-cycMSH4-13 was shown radiochemically stability and exhibited rapid and selective uptake in melanoma cells and tumors. Imaging studies yielded promising preclinical results, warranting further evaluation of 99mTc-HYNIC-cycMSH analogs as melanoma specific imaging agents.
Collapse
Affiliation(s)
- Vania Teixeira
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay
| | - Marcelo Fernández
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay
| | - Natalia Oddone
- Laboratorio de Señalización Celular y Nanobiología, Instituto de Investigaciones Biológicas Clemente Estable, Av. Italia 3318, CP 11600, Montevideo, Uruguay
| | - Xiuli Zhang
- Biochemistry Department, University of Missouri. Colombia
| | - Fabio Gallazzi
- Research Core Facilities, Univeristy of Missouri. Colombia
| | - Hugo Cerecetto
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear, Hospital de Clínicas "Dr. Manuel Quintela", Facultad de Medicina, Universidad de la República. Av. Italia s/n, Montevideo11600, Uruguay
| | - Williams Porcal
- Departamento de Química Orgánica, Facultad de Química, Universidad de la República, Av. General Flores 2124, Montevideo 11800, Uruguay
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, Montevideo 11400, Uruguay
| | - Thomas P Quinn
- Biochemistry Department, University of Missouri. Colombia
| |
Collapse
|
25
|
Cabral P, Cerecetto H. Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects. Anticancer Agents Med Chem 2017; 17:318-332. [PMID: 26953234 DOI: 10.2174/1871520616666160307142514] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Revised: 12/21/2015] [Accepted: 03/05/2016] [Indexed: 11/22/2022]
Abstract
Since its first description in 1955, tumor hypoxia has become a central issue in cancer treatment. Since then, it is essential to diagnose accurately the tumor oxygenation degree in order to establish the appropriate treatment. In this regard, a wide diversity of radiopharmaceuticals for in vivo imaging has been developed. Special conditions of the hypoxic microenvironment are low O2 partial pressure, enhanced levels of reductases, and genetic-adaptation-expression biomolecules involved in angiogenesis, erythropoiesis, cellular proliferation, apoptosis, metabolism- and glucose-uptake, local invasion, and metastatic spread. The development of radiolabeled hypoxia markers has been based on reductase substrates, like bioreductive ligands, or on entities capable of recognizing overexpressed proteins under hypoxia conditions, i.e. HIF-1α and carbonic anhydrase IX, among others. In this review these hypoxia markers are analyzed focusing on their medicinal chemistry characteristics.
Collapse
Affiliation(s)
- Pablo Cabral
- Centro de Investigaciones Nucleares, Facultad de Ciencias, Mataojo 2055, 11400 Montevideo, Uruguay
| | - Hugo Cerecetto
- Centro de Investigaciones Nucleares, Facultad de Ciencias, Mataojo 2055, 11400 Montevideo, Uruguay
| |
Collapse
|
26
|
Couto M, Mastandrea I, Cabrera M, Cabral P, Teixidor F, Cerecetto H, Viñas C. Frontispiece: Small-Molecule Kinase-Inhibitors-Loaded Boron Cluster as Hybrid Agents for Glioma-Cell-Targeting Therapy. Chemistry 2017. [DOI: 10.1002/chem.201783962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Marcos Couto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
- Institut de Ciències dels Materials de Barcelona; ICMAB-CSIC Campus UAB 08193 Bellaterra Spain
- Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Ignacio Mastandrea
- Centro Universitario Paysandú. CenUR Litoral Norte; Universidad de la República.; 60000 Paysandú Uruguay
- Instituto de Investigaciones Biológicas Clemente Estable; 11600 Montevideo Uruguay
| | - Mauricio Cabrera
- Centro Universitario Paysandú. CenUR Litoral Norte; Universidad de la República.; 60000 Paysandú Uruguay
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona; ICMAB-CSIC Campus UAB 08193 Bellaterra Spain
| | - Hugo Cerecetto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias; Universidad de la República; Iguá 4225 11400 Montevideo Uruguay
- Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias; Universidad de la República; Mataojo 2055 11400 Montevideo Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona; ICMAB-CSIC Campus UAB 08193 Bellaterra Spain
| |
Collapse
|
27
|
Couto M, Mastandrea I, Cabrera M, Cabral P, Teixidor F, Cerecetto H, Viñas C. Small-Molecule Kinase-Inhibitors-Loaded Boron Cluster as Hybrid Agents for Glioma-Cell-Targeting Therapy. Chemistry 2017; 23:9233-9238. [PMID: 28605114 DOI: 10.1002/chem.201701965] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Indexed: 12/30/2022]
Abstract
The reported new anilinoquinazoline-icosahedral borane hybrids have been evaluated as glioma targeting for potential use in cancer therapy. Their anti-glioma activity depends on hybrids' lipophilicity; the most powerful compound against glioma cells, a 1,7-closo-derivative, displayed at least 3.3 times higher activity than the parent drug erlotinib. According to the cytotoxic effects on normal glia cells, the hybrids were selective for epidermal growth factor receptor (EGFR)-overexpressed tumor cells. These boron carriers could be used to enrich glioma cancer cells with boron for cancer therapy.
Collapse
Affiliation(s)
- Marcos Couto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Institut de Ciències dels Materials de Barcelona, ICMAB-CSIC Campus UAB, 08193, Bellaterra, Spain.,Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Ignacio Mastandrea
- Centro Universitario Paysandú. CenUR Litoral Norte, Universidad de la República., 60000, Paysandú, Uruguay.,Instituto de Investigaciones Biológicas Clemente Estable, 11600, Montevideo, Uruguay
| | - Mauricio Cabrera
- Centro Universitario Paysandú. CenUR Litoral Norte, Universidad de la República., 60000, Paysandú, Uruguay
| | - Pablo Cabral
- Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Francesc Teixidor
- Institut de Ciències dels Materials de Barcelona, ICMAB-CSIC Campus UAB, 08193, Bellaterra, Spain
| | - Hugo Cerecetto
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Iguá 4225, 11400, Montevideo, Uruguay.,Área de Radiofarmacia, Centro de Investigaciones Nucleares Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400, Montevideo, Uruguay
| | - Clara Viñas
- Institut de Ciències dels Materials de Barcelona, ICMAB-CSIC Campus UAB, 08193, Bellaterra, Spain
| |
Collapse
|
28
|
Cabral P, Gambini J, Riva E, Chammas R, Alonso O, Fernandez M, Calzada V, Camacho X. 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma. Curr Radiopharm 2017; 10:21-28. [DOI: 10.2174/1874471009666161010155246] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 09/02/2016] [Accepted: 09/02/2016] [Indexed: 11/22/2022]
|
29
|
Camacho X, Machado CL, García MF, Gambini JP, Banchero A, Fernández M, Oddone N, Bertolini Zanatta D, Rosal C, Buchpiguel CA, Chammas R, Riva E, Cabral P. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. Oncology 2017; 92:229-242. [DOI: 10.1159/000452419] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 10/10/2016] [Indexed: 02/01/2023]
|
30
|
Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, Cabral P, Cerecetto H. Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept. Bioorg Med Chem 2016; 25:1163-1171. [PMID: 28089349 DOI: 10.1016/j.bmc.2016.12.026] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2016] [Revised: 12/05/2016] [Accepted: 12/19/2016] [Indexed: 11/26/2022]
Abstract
Aptamers are single-stranded oligonucleotides that recognize molecular targets with high affinity and specificity. Aptamer that selectively bind to the protein tyrosine kinase-7 (PTK7) receptor, overexpressed on many cancers, has been labelled as probes for molecular imaging of cancer. Two new PTK7-targeting aptamer probes were developed by coupling frameworks from the fluorescent dye AlexaFluor647 or the 6-hydrazinonicotinamide (HYNIC) chelator-labelled to 99mTc. The derivatizations via a 5'-aminohexyl terminal linker were done at room temperature and under mild buffer conditions. Physicochemical and biological controls for both imaging agents were performed verifying the integrity of the aptamer-conjugates by HPLC. Recognition of melanoma (B16F1) and lymphoma (A20) mouse cell lines by the aptamer was studied using cell binding, flow cytometry and confocal microscopy. Finally, in vivo imaging studies in tumour-bearing mice were performed. The new probes were able to bind to melanoma and lymphoma cell lines in vitro, the in vivo imaging in tumour-bearing mice showed different uptake behaviours showing for the fluorescent conjugate good uptake by B cell lymphoma while the radiolabelled conjugate did not display tumour uptake due to its high extravascular distribution, and both showed rapid clearance properties in tumour-bearing mice.
Collapse
Affiliation(s)
- Victoria Calzada
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay
| | - María Moreno
- Departamento de Desarrollo Biotecnológico-Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Jessica Newton
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Joel González
- Laboratorio de Experimentación Animal-Centro de Investigaciones Nucleares, Facultad de Ciencias-Universidad de la República, Montevideo, Uruguay
| | - Marcelo Fernández
- Laboratorio de Experimentación Animal-Centro de Investigaciones Nucleares, Facultad de Ciencias-Universidad de la República, Montevideo, Uruguay
| | - Juan Pablo Gambini
- Centro de Medicina Nuclear-Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay
| | - Manuel Ibarra
- Centro de Evaluación de Biodisponibilidad y Bioequivalencia de Medicamentos, Universidad de la República, Montevideo, Uruguay
| | - Alejandro Chabalgoity
- Departamento de Desarrollo Biotecnológico-Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
| | - Susan Deutscher
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Thomas Quinn
- Department of Biochemistry, University of Missouri, Columbia, MO, USA; Harry S Truman Veterans' Administration Hospital, Columbia, MO, USA
| | - Pablo Cabral
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay
| | - Hugo Cerecetto
- Área de Radiofarmacia-Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, 11400 Montevideo, Uruguay.
| |
Collapse
|
31
|
Calzada V, Fernanda García M, Michel Alonso-Martínez L, Camachoc X, Goicochea E, Fernández M, Xiques Castillo A, Díaz-Miqueli A, Iznaga-Escobar N, Leyva Montaña R, Alonso O, Pablo Gambini J, Cabral P. Fab(nimotuzumab)-HYNIC-99mTc: Antibody Fragmentation for Molecular Imaging Agents. Anticancer Agents Med Chem 2016; 16:1184-9. [DOI: 10.2174/1871520616666160310143828] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 12/07/2015] [Accepted: 03/08/2016] [Indexed: 11/22/2022]
|
32
|
Kovacs L, Tassano M, Cabrera M, Zamboni CB, Fernández M, Anjos RM, Cabral P. Development of 177Lu-DOTA-Dendrimer and Determination of Its Effect on Metal and Ion Levels in Tumor Tissue. Cancer Biother Radiopharm 2015; 30:405-9. [DOI: 10.1089/cbr.2014.1675] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Luciana Kovacs
- Centro do Reator de Pesquisas (CRPq), Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN - SP), São Paulo, Brasil
| | - Marcos Tassano
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Mirel Cabrera
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Cibele B. Zamboni
- Centro do Reator de Pesquisas (CRPq), Instituto de Pesquisas Energéticas e Nucleares (IPEN/CNEN - SP), São Paulo, Brasil
| | - Marcelo Fernández
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| | - Roberto M. Anjos
- Instituto de Física, Universidade Federal Fluminense, Niterói, Brasil
| | - Pablo Cabral
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Universidad de la República, Montevideo, Uruguay
| |
Collapse
|
33
|
Feger C, Cabral P, Basque D, Levrel H, Chambolle M. Grand cycle de l’eau, évaluation des services écosystémiques et aménagement du territoire : un premier retour d’expérience. ACTA ACUST UNITED AC 2015. [DOI: 10.1051/tsm/201509056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
34
|
Cabral P, Gonzalez-Vicente A, Hong N, Garvin J. Abstract P103: Cellular Stretch Induces Higher Intracellular Calcium Increases in Dahl Salt-Sensitive Than Salt-Resistant Rat Thick Ascending Limbs: Role of Transient Receptor Potential Vanilloid 4. Hypertension 2015. [DOI: 10.1161/hyp.66.suppl_1.p103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The thick ascending limb (TAL) reabsorbs 30 % of the filtered NaCl playing a pivotal role in the regulation of salt homeostasis. Abnormal reabsorption of NaCl in this segment causes salt-sensitive hypertension. We showed that flow-induced cellular stretch stimulates superoxide production in epithelial cells from TALs. Dahl salt-sensitive rat (DSS) TALs produce more superoxide than those from salt-resistant rats (DSR). Mechanical stimulation exerted by cellular stretch increases intracellular calcium (Cai) in several types of cells. We have shown that luminal flow-induced increases in Cai is mediated by Transient Receptor Potential Vanilloid (TRPV4). Therefore, we hypothesized that cellular stretch increases Cai in TALs from DSS rats more than those from DSR rats due to elevated TRPV4 activity. We measured Cai using the calcium-sensitive dye Fura-2 in isolated, perfused DSR and DSS TALs. Cellular stretch increased Cai by 243 ± 51 nM in DSS TALs (n=9; p<0.0008 vs. no stretch conditions) and by 124 ± 27 nM in DSR TALs (n=10; p<0.0005 vs no stretch conditions). Cellular stretch-induced Cai increases were significantly higher in the DSS group (p<0.05 vs DSR). When these animals were fed a high-salt diet (4% NaCl) similar responses were obtained. Cellular stretch increased Cai by 236 ± 58 nM in DSS TALs (n=7; p<0.004 vs no stretch conditions) and by 92 ± 15 nM in DSR TALs (n=6; p<0.0008 vs no stretch conditions). To study whether DSS and DSR TALs express different amounts of TRPV4 we performed Western blots. We found that TRPV4 protein expression was similar in TALs lysates from both strains fed either a control standard or a high-salt diet. We then tested the effects of transfecting DSS TALs with TRPV4-small hairpin (sh) RNA on stretch-induced Cai increases. Under these circumstances, the difference in stretch-induced Cai increases between DSS and DSR TALs was not significant (75 ± 15 nM in DSS vs 56 ± 28 nM vs DSR, n=4 for each group) . We conclude that DSS TALs are more sensitive to increases in cellular stretch than DSR TALs possibly due to enhanced TRPV4 activity.
Collapse
Affiliation(s)
| | | | - Nancy Hong
- Case Western Reserve Univ, Cleveland, OH
| | | |
Collapse
|
35
|
Dapueto R, Aguiar RB, Moreno M, Machado CML, Marques FLN, Gambini JP, Chammas R, Cabral P, Porcal W. Technetium glucose complexes as potential cancer imaging agents. Bioorg Med Chem Lett 2015; 25:4254-9. [PMID: 26318991 DOI: 10.1016/j.bmcl.2015.07.098] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 07/26/2015] [Accepted: 07/29/2015] [Indexed: 11/30/2022]
Abstract
GLUT's (facilitative glucose transporters) over-expression in tumor cells has allowed the detection of several cancer types, using a glucose analogue ((18)F-FDG) with PET images, worldwide. New glucose analogs radiolabeled with (99m)Tc could be a less-expensive and more accessible alternative for diagnosis using SPECT imaging. d-Glucose ((99m)Tc-IDAG) and 2-d-deoxyglucose ((99m)Tc-AADG) organometallic complexes were proposed and studied as potential (18)F-FDG surrogates. The glucose complexes were prepared and evaluated as potential cancer imaging agents, in a melanoma tumor model. Iminodiacetic acid (IDA) and aminoacetate (AA) moieties were chosen as chelating system for radiolabeling with (99m)Tc. Tumor uptake of the formed complexes was evaluated in B16 murine cell line in vitro and in vivo in melanoma bearing C57BL/6 mice. In vitro and in vivo studies were conducted with (18)F-FDG in order to compare the uptake of (99m)Tc-glucose complexes in the tumor model. IDAG and AADG compounds were synthesized and radiolabeled with (99m)TcO4(-) to obtain the (99m)Tc-IDAG and (99m)Tc-AADG complexes in high yield and stability. In vitro cell studies showed maximum uptake at 60 min for complexes, (99m)Tc-IDAG and (99m)Tc-AADG, with 6% and 2%, respectively. Biodistribution studies showed high tumor uptake one hour post-injection, reaching tumor-to-muscle ratios of 12.1 ± 3.73 and 2.88 ± 1.40 for (99m)Tc-IDAG and (99m)Tc-AADG, respectively. SPECT and micro-SPECT-CT images acquired after the injection of (99m)Tc-IDAG showed accumulation in tumor sites, suggesting that this glucose complex would be a promising candidate for cancer imaging.
Collapse
Affiliation(s)
- Rosina Dapueto
- Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400 Montevideo, Uruguay; Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay
| | - Rodrigo B Aguiar
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Av. Dr. Arnaldo, 251, São Paulo 01246-903, Brazil
| | - María Moreno
- Departamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la Republica, Av. Alfredo Navarro 3051, 11600 Montevideo, Uruguay
| | - Camila M L Machado
- Centro de Medicina Nuclear, Faculdade de Medicina, Universidade de São Paulo, Trav. R. Dr. Ovidio Pires de Campos s/n, São Paulo 05403-010, Brazil
| | - Fabio L N Marques
- Centro de Medicina Nuclear, Faculdade de Medicina, Universidade de São Paulo, Trav. R. Dr. Ovidio Pires de Campos s/n, São Paulo 05403-010, Brazil
| | - Juan P Gambini
- Centro de Medicina Nuclear, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Av Italia s/n, 11600 Montevideo, Uruguay
| | - Roger Chammas
- Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Av. Dr. Arnaldo, 251, São Paulo 01246-903, Brazil
| | - Pablo Cabral
- Laboratorio de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Mataojo 2055, 11400 Montevideo, Uruguay.
| | - Williams Porcal
- Grupo de Química Medicinal, Laboratorio de Química Orgánica, Facultad de Ciencias-Facultad de Química, Universidad de la República, Iguá 4225, 11400 Montevideo, Uruguay.
| |
Collapse
|
36
|
Garcia MF, Zhang X, Gallazzi F, Fernandez M, Moreno M, Gambini JP, Porcal W, Cabral P, Quinn TP. Evaluation of tricine and EDDA as Co-ligands for 99mTc-labeled HYNIC-MSH analogs for melanoma imaging. Anticancer Agents Med Chem 2015; 15:122-30. [PMID: 25175799 DOI: 10.2174/1871520614666140825123150] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 07/27/2014] [Accepted: 08/03/2014] [Indexed: 11/22/2022]
Abstract
Several radiolabeled alpha-melanocyte stimulating hormone (α-MSH) analogs have been studied for their abilities to target melanoma tumor cells through specific recognition and binding to the melanocortin receptor 1 (MCR1). In this work, a lactam bridgecyclized α-MSH analog was labeled with (99m) via the hydrazinonicotinamide (HYNIC) chelator and characterized for its melanoma tumor targeting properties. The bifunctional chelating agent HYNIC-Boc was attached to the N-terminus of the MSH peptide followed by the lactam cyclization, resulting in the HYNIC-cyc-MSH analog. The lactam cyclized peptide displayed high affinity and specificity for MC1-receptors present on B16/F1 melanoma tumor cells, exhibiting an IC50 of 6.48 nM. HYNIC-cyc-MSH was radiolabeled with (99m)Tc using two common co-ligands, tricine and EDDA. In vitro, the radiochemical stability, cell binding and efflux properties were similar between the peptides radiolabeled with tricine and EDDA as co-ligands. In vivo, biodistribution studies (n=4) demonstrated that (99m)Tc- HYNIC-cyc-MSH/tricine had superior tumor to muscle and tumor to blood ratios than (99m)Tc-HYNIC-cyc-MSH/EDDA at early time points. Planar gamma imaging of melanoma bearing mice showed that 99mTc-HYNIC-cyc-MSH/tricine was able to clearly visualize tumors, underscoring the potential utility of (99m)Tc labeled lactam cyclized MSH molecules as melanoma imaging agents.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Thomas P Quinn
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Mataojo 2055, Montevideo 11400, Uruguay.
| |
Collapse
|
37
|
Fresco R, Spera G, Meyer C, Cabral P, Mackey JR. Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. Oncologist 2015; 20:702-12. [PMID: 26025934 PMCID: PMC4492226 DOI: 10.1634/theoncologist.2014-0295] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 03/05/2015] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Medical imaging is commonly required in breast cancer (BC) clinical trials to assess the efficacy and/or safety of study interventions. Despite the lack of definitive epidemiological data linking imaging radiation with cancer development in adults, concerns exist about the risks of imaging radiation-induced malignancies (IRIMs) in subjects exposed to repetitive imaging. We estimated the imaging radiation dose and IRIM risk in subjects participating in BC trials. MATERIALS AND METHODS The imaging protocol requirements in 10 phase III trials in the adjuvant and advanced settings were assessed to estimate the effective radiation dose received by a typical and fully compliant subject in each trial. For each study, the excess lifetime attributable cancer risk (LAR) was calculated using the National Cancer Institute's Radiation Risk Assessment Tool, version 3.7.1. Dose and risk calculations were performed for both imaging intensive and nonintensive approaches to reflect the variability in imaging performed within the studies. RESULTS The total effective imaging radiation dose was 0.4-262.2 mSv in adjuvant trials and 26-241.3 mSv in metastatic studies. The dose variability resulted from differing protocol requirements and imaging intensity approaches, with computed tomography, multigated acquisition scans, and bone scans as the major contributors. The mean LAR was 1.87-2,410/100,000 in adjuvant trials (IRIM: 0.0002%-2.41% of randomized subjects) and 6.9-67.3/100,000 in metastatic studies (IRIM: 0.007%-0.067% of subjects). CONCLUSION IRIMs are infrequent events. In adjuvant trials, aligning the protocol requirements with the clinical guidelines' surveillance recommendations and substituting radiating procedures with equivalent nonradiating ones would reduce IRIM risk. No significant risk has been observed in metastatic trials, and potential concerns on IRIMs are not justified. IMPLICATIONS FOR PRACTICE Medical imaging is key in breast cancer (BC) clinical trials. Most of these procedures expose patients to ionizing radiation, and the risk of second cancer development after imaging has prompted recent concerns and controversy. Using accepted calculation models, the number of malignancies were estimated that were potentially attributable to the imaging procedures performed during a patient's participation in BC clinical trials. The results show that for patients participating in metastatic trials, the risk of imaging radiation-induced malignancies is negligible. In adjuvant trials, some second cancers due to imaging could be expected, and measures can be taken to reduce their risk.
Collapse
Affiliation(s)
- Rodrigo Fresco
- Medical Lead Department, Translational Research in Oncology, Montevideo, Uruguay; Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Gonzalo Spera
- Medical Lead Department, Translational Research in Oncology, Montevideo, Uruguay; Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Carlos Meyer
- Medical Lead Department, Translational Research in Oncology, Montevideo, Uruguay; Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Pablo Cabral
- Medical Lead Department, Translational Research in Oncology, Montevideo, Uruguay; Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - John R Mackey
- Medical Lead Department, Translational Research in Oncology, Montevideo, Uruguay; Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
38
|
Cabral P, Gonzalez‐Vicente A, Garvin J. Stretch Increases Intracellular Calcium More in Dahl‐Salt‐Sensitive than Salt‐Resistant Rat Thick Ascending Limbs. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.960.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Pablo Cabral
- Physiology and BiophysicsCase Western Reserve UniversityClevelandOHUnited States
| | | | - Jeffrey Garvin
- Physiology and BiophysicsCase Western Reserve UniversityClevelandOHUnited States
| |
Collapse
|
39
|
Rossotti MA, González-Techera A, Guarnaschelli J, Yim L, Camacho X, Fernández M, Cabral P, Leizagoyen C, Chabalgoity JA, González-Sapienza G. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain. MAbs 2015; 7:820-8. [PMID: 26192995 PMCID: PMC4622952 DOI: 10.1080/19420862.2015.1068491] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 06/24/2015] [Accepted: 06/26/2015] [Indexed: 02/08/2023] Open
Abstract
Recombinant single domain antibodies (nanobodies) constitute an attractive alternative for the production of neutralizing therapeutic agents. Their small size warrants rapid bioavailability and fast penetration to sites of toxin uptake, but also rapid renal clearance, which negatively affects their performance. In this work, we present a new strategy to drastically improve the neutralizing potency of single domain antibodies based on their fusion to a second nanobody specific for the complement receptor CD11b/CD18 (Mac-1). These bispecific antibodies retain a small size (~30 kDa), but acquire effector functions that promote the elimination of the toxin-immunocomplexes. The principle was demonstrated in a mouse model of lethal toxicity with tetanus toxin. Three anti-tetanus toxin nanobodies were selected and characterized in terms of overlapping epitopes and inhibition of toxin binding to neuron gangliosides. Bispecific constructs of the most promising monodomain antibodies were built using anti Mac-1, CD45 and MHC II nanobodies. When co-administered with the toxin, all bispecific antibodies showed higher toxin-neutralizing capacity than the monomeric ones, but only their fusion to the anti-endocytic receptor Mac-1 nanobody allowed the mice to survive a 10-fold lethal dose. In a model of delayed neutralization of the toxin, the anti- Mac-1 bispecific antibodies outperformed a sheep anti-toxin polyclonal IgG that had shown similar neutralization potency in the co-administration experiments. This strategy should have widespread application in the development of nanobody-based neutralizing therapeutics, which can be produced economically and more safely than conventional antisera.
Collapse
Affiliation(s)
- Martin A Rossotti
- Cátedra de Inmunología; DEPBIO; Facultad de Química; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
| | - Andrés González-Techera
- Cátedra de Inmunología; DEPBIO; Facultad de Química; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
| | - Julio Guarnaschelli
- Departamento de Biotecnología; Facultad de Medicina; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
- Prondil S.A.; Montevideo, Uruguay
| | - Lucia Yim
- Departamento de Biotecnología; Facultad de Medicina; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
| | - Ximena Camacho
- Departamento de Radiofarmacia; Centro de Investigaciones Nucleares; Facultad de Ciencias; Universidad de la República; Montevideo, Uruguay
| | - Marcelo Fernández
- Departamento de Radiofarmacia; Centro de Investigaciones Nucleares; Facultad de Ciencias; Universidad de la República; Montevideo, Uruguay
| | - Pablo Cabral
- Departamento de Radiofarmacia; Centro de Investigaciones Nucleares; Facultad de Ciencias; Universidad de la República; Montevideo, Uruguay
| | | | - José A Chabalgoity
- Departamento de Biotecnología; Facultad de Medicina; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
| | - Gualberto González-Sapienza
- Cátedra de Inmunología; DEPBIO; Facultad de Química; Instituto de Higiene; Universidad de la República; Montevideo, Uruguay
| |
Collapse
|
40
|
Kovacs L, Tassano M, Cabrera M, Fernandez M, Porcal W, Anjos R, Cabral P. Labeling Polyamidoamine (PAMAM) Dendrimers with Technetium-99m via Hydrazinonicotinamide (HYNIC). Curr Radiopharm 2014; 7:115-22. [DOI: 10.2174/1874471007666140825121615] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2014] [Revised: 07/22/2014] [Accepted: 08/12/2014] [Indexed: 11/22/2022]
|
41
|
Garcia MF, Calzada V, Camacho X, Goicochea E, Gambini J, Quinn T, Porcal W, Cabral P. Microwave-assisted Synthesis of HYNIC Protected Analogue for 99mTc Labeled Antibody. Curr Radiopharm 2014; 7:84-90. [DOI: 10.2174/1874471007666141128160449] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Revised: 11/20/2014] [Accepted: 11/28/2014] [Indexed: 11/22/2022]
|
42
|
Zhang X, Teixeira V, Porcal W, Cabral P, Gambini JP, Fernandez M, Gallazzi F, Quinn T. [ 99mTc(CO) 3] + and [ 99mTcO 2] + Radiolabeled Cyclic Melanotropin Peptides for Melanoma SPECT Imaging. Curr Radiopharm 2014; 7:63-74. [DOI: 10.2174/1874471007666140715094554] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2014] [Revised: 07/06/2014] [Accepted: 07/15/2014] [Indexed: 11/22/2022]
|
43
|
Kovacs L, Tassano M, Cabrera M, Fernández M, Anjos R, Cabral P, Porcal W. Labelling PAMAM dendrimers with Tc-99m via HYNIC. Nucl Med Biol 2014. [DOI: 10.1016/j.nucmedbio.2014.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
44
|
Dapueto R, Fernández M, Aguiar R, Moreno M, Machado C, Marques F, Gambini JP, Chammas R, Cabral P, Porcal W. Biological evaluation of two glucose derivatives radiolabeled with 99mTc as potential cancer imaging agents. Nucl Med Biol 2014. [DOI: 10.1016/j.nucmedbio.2014.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
45
|
Cabral P, Garvin J. Shear stress and cellular stretch induces intracellular calcium increases in the thick ascending limb: role of transient receptor potential vanilloid 4 (892.3). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.892.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Pablo Cabral
- Physiology and Biophysics Case Western Reserve UniversityClevelandOHUnited States
| | - Jeffrey Garvin
- Physiology and Biophysics Case Western Reserve UniversityClevelandOHUnited States
| |
Collapse
|
46
|
Camacho X, García MF, Calzada V, Fernández M, Porcal W, Alonso O, Gambini JP, Cabral P. Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab. Curr Radiopharm 2013; 6:12-9. [PMID: 23035645 DOI: 10.2174/1874471011306010003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 09/29/2012] [Accepted: 01/10/2013] [Indexed: 11/22/2022]
Abstract
Vascular endothelial growth factor (VEGF) is one of the classic factors involved in tumor-induced angiognesis in several solid tumors. Bevacizumab, a monoclonal antibody against VEGF, can be used as an imaging tool in preclinical studies. The aim of this study was to radiolabel Bevacizumab with (99m)Tc and to evaluate in vivo its imaging properties in an adenocarcinoma animal model. For this purpose, Bevacizumab was derivatized with Suc-HYNIC as a bifunctional coupling agent. A mixture of Tricine/SnCl(2).2H(2)O was added to Bevacizumab-HYNIC and radiolabeled with (99m)TcO(4)(-). The radiochemical stability of the radiolabeled antibody was assessed. Biodistribution and scintigraphy imaging were performed in normal CD1 female mice and in spontaneous adenocarcinoma tumor bearing CD1 mice (n = 5). We demonstrated that 99mTc-HYNIC-Bevacizumab was stable. In vivo biodistribution studies revealed that tumor uptake of (99m)Tc-HYNIC-Bevacizumab was 1.37 ± 0.51% and 5.33 ± 2.13% at 4 and 24 h postinjection, respectively. Scintigraphy image studies showed tumor selective uptake of (99m)Tc-HYNIC-Bevacizumab in the tumor-bearing mice. We conclude that (99m)Tc-HYNIC-Bevacizumb has the potential to be used as a tracer for tumor imaging in preclinical studies.
Collapse
Affiliation(s)
- Ximena Camacho
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Cabral P, Hong N, Garvin J. Abstract 41: Fructose Stimulates Na/H Exchanger 3 Activity and Enhances the Ability of Angiotensin II to Activate Na/H Exchanger 3 in the Proximal Tubule. Hypertension 2013. [DOI: 10.1161/hyp.62.suppl_1.a41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Consumption of high-fructose corn syrup as a sweetener has increased dramatically. Fructose has been implicated in the epidemic of diabetes, obesity and hypertension including salt-sensitive hypertension. However, the mechanisms are poorly understood. The proximal nephron reabsorbs 60-70% of the fluid and Na, and most of the filtered bicarbonate via Na/H exchanger 3. Enhanced proximal nephron transport has been implicated in several forms of hypertension. We hypothesized that fructose stimulates NHE3 activity and enhances the ability of angiotensin II (ANG II) to activate NHE3 in the proximal tubule. To test our hypothesis we isolated and perfused proximal tubules from Sprague Dawley rats. NHE3 activity was measured as the recovery of intracellular pH after an NH4Cl acid pulse using the pH sensitive dye BCECF. The rate of pH recovery was measured in Fluorescent Units per second (FU/sec). In the presence of a 5.5 mM glucose-containing physiological saline the basal rate of pH recovery was 3.1 ± 0.8 FU/sec. When the luminal solution was exchanged to a 0.6 mM glucose + 5 mM fructose-containing physiological saline in a second period, the rate of pH recovery increased to 5 ± 1 FU/sec (p<0.03, n=8).To study whether this effect was due to the addition of fructose or the removal of glucose to the lumen, we performed a separate set of experiments where 5 mM glucose was substituted for 5 mM fructose. In the presence of 0.6 mM glucose the basal rate of pH recovery was 3.6 ± 1.5 FU/sec. When 5 mM fructose was added the rate of pH recovery increased to 5.9 ± 2 FU/sec (p<0.02, n=5). Control experiments showed no differences between periods when 5 mm glucose was added back to the luminal perfusate. Finally, we tested the effect of low concentrations of ANG II in the presence or absence of luminal fructose. In the presence of 5.5 mM glucose, ANG II 10-12 M did not affect the rate of pH recovery (change: -1.1 ± 0.5 FU/sec, n=9). However, in the presence of 5 mM fructose, ANG II increased the rate of pH recovery (change: 4.0 ± 2.2 FU/sec, p< 0.03 n=6). We conclude that acute treatment with fructose stimulates NHE3 activity and enhances the ability of ANG II to activate NHE3 in the proximal tubule. These results may partially explain the mechanism by which a fructose diet induces hypertension.
Collapse
Affiliation(s)
| | - Nancy Hong
- Case Western Reserve Univ, Cleveland, OH
| | | |
Collapse
|
48
|
Calzada V, Garcia F, Fernández M, Porcal W, Quinn T, Alonso O, Gambini JP, Cabral P. Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer. World J Nucl Med 2013; 12:27-32. [PMID: 23961253 PMCID: PMC3745630 DOI: 10.4103/1450-1147.113953] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The amplification of HER2 gene has been described in several tumor types, mainly breast cancer with a subsequent increase in HER2 protein expression. Trastuzumab is a humanized monoclonal antibody that recognizes selectively the HER2 extracellular domain. The objective of the present work was to standardize the conjugation of Trastuzumab with Succinimidyl-hydrazinonicotinamide (HYNIC) and labeling with 99mTc to obtain 99mTc-HYNIC-Trastuzumab for use as in vivo tracer of the HER2 expression in breast cancer. The labeling procedure involved derivatization of 0.067 μmol of Trastuzumab with 0.33 μmols of HYNIC in dimethyl sulfoxide (DMSO). The mixture was incubated for 30 min. A mixture of Tricine and SnCl2.2H2O was prepared by add a solution of 44.6 μmols Tricine in 0.05 mL HCl 2.0 M and a similar volume of another solution containing 44.3 μmols SnCl2.2H2O in 0.5 mL HCl 2.0 M. Then, 0.05 mL of this mixed was added to the conjugated with 296 MBq of 99mTcO-4. The final mixture was incubated at room temperature (18-25°C) for 30 min. Radiochemical purity of the labeled solution was studied by chromatography, to evaluate 99mTc-Tricine, 99mTcO2.H2O, and free 99mTcO4−. Radiochemical purity was also evaluated by HPLC. Stability studies were tested in solution at 4°C and lyophilized at 4°C. Biodistribution studies were performed in healthy CD-1 female mice at 2, 5, and 24 h (n = 3) and CD-1 female mice spontaneous breast adenocarcinoma (n = 3). Scintigraphic images of spontaneous breast adenocarcinoma in female CD-1 mice were acquired in a gamma camera at 2, 5, and 24 h post-injection. Labeling was easily performed with high yields (>90%) and radiopharmaceutical stability for 24 h post-labeling. Stability studies revealed that antibody derivative must be lyophilized for undamaged storage. Biodistribution studies and imaging revealed excellent uptake in the tumor. Based on the results it was concluded that 99mTc-HYNIC-Trastuzumab could be a promising radiopharmaceutical for in vivo diagnosis of the HER2 status in breast with impact on treatment planning.
Collapse
Affiliation(s)
- Victoria Calzada
- Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la Republica, Montevideo, Uruguay
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Calzada V, Zhang X, Fernandez M, Diaz-Miqueli A, Iznaga-Escobar N, Deutscher SL, Balter H, Quinn TP, Cabral P. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab. Curr Radiopharm 2013; 5:318-24. [PMID: 22280117 DOI: 10.2174/1874471011205040318] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2011] [Revised: 11/15/2011] [Accepted: 12/10/2011] [Indexed: 11/22/2022]
Abstract
In this work Nimotuzumab (monoclonal antibody, recognizes the EGF-R) was radiolabeled with (177)Lu as a potential cancer therapy radiopharmaceutical. In-vitro cell binding studies and in-vivo biodistribution and imaging studies were performed to determine the radiochemical stability, targeting specificity and pharmacokinetics of the (177)Lu-labeled antibody. Nimotuzumab was derivatized with DOTA-NHS at room temperature for 2 hours. DOTA-Nimotuzumab was radiolabeled with (177)LuCl3 (15 MBq/mg) at 37°C for 1 h. The radiochemical purity was assessed by ITLC, silica gel and by RP-HPLC. Binding specificity studies were performed with EGF-R positive A431 human epithelial carcinoma and EGF-R negative MDA-MB-435 breast carcinoma cells. Biodistribution studies were performed in healthy female CD-1 mice at 1 h, 4 h, 24 h, and A431 xenografted nude mice at 10 min, 1 h, 4 h, 24 h, 48 h, and 96 h. SPECT-CT imaging studies were performed in A431 xenografted mice at 24 h post injection. DOTA-Nimotuzumab was efficiently labeled with (177) LuCl(3) at 37°C. The in vitro stability of labeled product was optimal over 24 h in buffered saline and mouse serum. Specific recognition of EGF-R by (177)Lu-DOTA-Nimotuzumab was observed in A431 cell binding studies. Biodistribution studies demonstrated increasing tumor uptake of (177)Lu-DOTA-Nimotuzumab over time, with tumor to muscle ratios of 6.26, 10.68, and 18.82 at 4 h, 24 h, and 96 h post injection. Imaging of A431 xenografted mice showed high uptake in the tumor. (177)Lu-DOTA-Nimotuzumab has the potential to be a promising therapy agent, which may be useful in the treatment of patients with EGF-R positive cancer.
Collapse
|
50
|
Camacho X, García MF, Calzada V, Fernández M, Chabalgoity JA, Moreno M, Barbosa de Aguiar R, Alonso O, Gambini JP, Chammas R, Cabral P. [(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model. Oncology 2013; 84:200-9. [PMID: 23328435 DOI: 10.1159/000338961] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Accepted: 04/19/2012] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Vascular endothelial growth factor (VEGF) is one of the classic factors to tumor-induced angiogenesis in several tumor types, including melanoma. Bevacizumab, a monoclonal antibody against VEGF, could be used as an imaging tool in preclinical studies. OBJECTIVE To radiolabel bevacizumab with [(99m)Tc(CO)3(OH2)3](+) and evaluate it in vivo and in vitro for melanoma imaging properties. METHODS Bevacizumab was radiolabeled with [(99m)Tc(CO)3(OH2)3](+) ion in saline. The radiochemical stability of the labeled antibody was assessed. The biodistribution and scintigraphy imaging of the radiolabeled antibody were evaluated in normal C57BL/6J mice and in C57BL/6J mice bearing murine B16F1 melanoma tumors. Immunoreactivity of bevacizumab to murine tumors was determined from direct immunofluorescence and immunoblotting assays. RESULTS We demonstrate that (99m)Tc(CO)3-bevacizumab was stable. In vivo biodistribution studies revealed that tumor uptake of (99m)Tc(CO)3-bevacizumab was 2.64 and 2.51 %ID/g at 4 and 24 h postinjection. Scintigraphy image studies showed tumor selective uptake of (99m)Tc(CO)3-bevacizumab in the tumor-bearing mice. This affinity was confirmed by immunoassays performed on B16F10 tumor samples. CONCLUSIONS (99m)Tc(CO)3-bevacizumab could be used as an approach for tumor nuclear imaging in preclinical studies. This should be useful to provide insights into the angiogenic stimulus before and after chemotherapy, which might help improve current antitumor therapy.
Collapse
Affiliation(s)
- Ximena Camacho
- Departamento de Radiofarmacia, Centro de Investigaciones Nucleares, Facultad de Ciencias, Universidad de la República, Montevideo, Uruguay
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|